Brief: Supernus Pharmaceuticals Releases New Data From Phase 2A Study Of Spn-820
30/10/2024 22:32
Supernus Pharmaceuticals Inc SUPN.O :
* SUPERNUS PHARMACEUTICALS : RELEASES NEW DATA FROM PHASE 2A
STUDY
OF SPN-820
* SUPERNUS PHARMACEUTICALS : SPN-820 SHOWS 50% MADRS
RESPONSE
RATE, 35% REMISSION RATE AT 4 HOURS
Source text: ID:n0001356576-24-000062
Further company coverage: SUPN.O
Recent news on Supernus Pharmaceuticals
See all newsHuron Consulting poised to hit fresh record ahead of S&P SmallCap addition
Brief: S&P Dow Jones Indices Msg Rangers And Huron Consulting Group Set To Join S&P Smallcap 600
Brief: Supernus Pharmaceuticals Says FDA Grants Seven Years Orphan-Drug Exclusivity For Onapgo
Supernus Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
U.S. STOCKS ON THE MOVE -Micron Technology, Ares Management, Boeing